Symplicity Spyral Renal Denervation System
Medtronic, Inc. · Decision date Nov 17, 2023
What did the FDA approve?
FDA records P220026 as an original PMA application. The recorded decision is approval, dated Nov 17, 2023.
FDA approval order statement
The Symplicity Spyral Multi-Electrode Renal Denervation Catheter and the Symplicity G3 RF Generator are indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 17, 2023
Regulatory record facts
- Identifier
- P220026
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- Decision code
- APPR
- Decision date
- Nov 17, 2023
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ablation catheter, renal denervation.
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P220026 received
Application receipt date recorded by FDA.
P220026 · FDA decision
APPR
P220026/S014 · Related supplement
Symplicity Spyral Renal Denervation System
P220026/S019 · Related supplement
Symplicity G3 Renal Denervation RF Generator
Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Symplicity Spyral Renal Denervation SystemP220026/S014 | Medtronic, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Symplicity G3 Renal Denervation RF GeneratorP220026/S019 | Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P220026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
